Figure 4. TH-302 has anti-leukemia activity in an in vivo primary AML xenograft murine model.

TH-302 (50 mg/kg intraperitoneally 3 times a week for 3 weeks) reduced the number of circulating AML cells and prolonged survival of NSG mice engrafted with primary AML cells compared to the vehicle-treated mice. A. Survival curves (N=8/group) of vehicle-treated (control) and TH-302–treated mice. Line indicates onset and duration of treatment. B. Total numbers of mononuclear cells (MN) or total human AML cells were determined in blood by FACS analysis after staining for huCD45 (N=2 and 3 for control and TH-302–treated mice, respectively). C. PIMO immunostaining of BM sections from control or TH-302–treated mice euthanized at the end of the treatment; 20 × magnification. D. Survival curves of secondary transplant mice (N=5/group). NSG mice were transplanted with 0.01 or 0.005×10⁶ BM cells isolated from primary recipients (A) treated with control or TH-302. * P<0.05; ** P<0.01; *** P<0.001.